Ideally, the clinician would have access to an algorithm of biomarker assays to help identify those patients who might (or, alternatively, should not) be candidates for a safe treatment interruption (TI).
Several novel herbs have been selected by using logical computational algorithms and assayed on six cancerous cell lines.
We used a sequential testing algorithm with three immunoenzymatic assays (EIA), which detect anti-HIV antibodies.
Rather, they suggested a combination of several approaches, including use of analytical algorithms, host cell reactivation assays in an isogenic background and estimation of protein expression levels.
The algorithm reduces the variability of assays performed across different reagent and array batches, methods of sample preservation, multiple personnel, and among different laboratories.
An MK algorithm enhances assay sensitivity while providing results 24 48 h sooner than the traditional mouse embryo assay (MEA).
Further, recent infection testing algorithms using a multiple incidence assays in combination with additional clinical (e.g., CD4 cell count, RNA testing), laboratory (e.g., ART testing), and historical information should be explored for improving the accuracy of assay-derived incidence estimates.
(48) The use of stepwise algorithms, which combine different HPV assays, may compensate for the limitations of individual tests and should now be considered in clinical settings.
By comparing the BER complementation assays with these algorithms, we could evaluate the abilities of these programs to make functional predictions.
eMERGE-II is developing T1 applications such as genomic risk prediction algorithms and clinically validated PGx assays, while continuing T0 discovery research through GWAS and phenome-wide association studies.
